CISPLATIN | A074735 | FRESENIUS KABI USA LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition From Lachman Consultant Services, Inc. FDA-2014-P-0284 · 3 docket documents Lachman Consultant Services, Inc. filed this petition under Section 505(j)(2)(C) of the FDC Act requesting that the FDA declare Cisplatin Injection 1 mg/mL in strengths of 10 mg/10 mL and 25 mg/25 mL suitable for submission in an ANDA, representing a change in total drug content from the listed drug | Other | 2014-03-14 | Withdrawn | Lachman Consultant Services, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.